Are there Western clinical trials of Selank?

No substantial Western clinical programme exists, and no Western regulator has assessed it.

Why does tuftsin have more papers than Selank?

Tuftsin has been studied immunologically for decades independently of Selank. Most of that literature is not about Selank.

Which paper is the best starting point?

The 2001 Bulletin of Experimental Biology and Medicine paper on enkephalin-degrading enzymes, PMID 11550013, describes the most specific reported mechanism.

Selank (Tuftsin Analogue)

Selank in the Published Literature

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-234 cited sources

PubMed indexes roughly 135 Selank records. Mechanistic work — enkephalinase inhibition, BDNF expression, behavioural models — appears in international journals and is conducted in rodents. Clinical work is concentrated in Russian-language publications, principally the Korsakov Journal of Neurology and Psychiatry.

Key facts

Selank PubMed records: ~135
Tuftsin PubMed records: ~690
Mechanistic journals: Bull Exp Biol Med, Dokl Biol Sci
Clinical journal: Zh Nevrol Psikhiatr Im S S Korsakova
Model organism: Predominantly rat
Earliest key mechanism paper: 2001 (PMID 11550013)
Western regulatory review: None

The shape of the evidence

Selank's literature splits the same way Semax's does, which is unsurprising given the shared institute. Mechanistic and preclinical work appears in internationally indexed journals — the Bulletin of Experimental Biology and Medicine, Doklady Biological Sciences — and is accessible in English. Clinical work sits largely in Russian-language publications, indexed by translated title and often without accessible English full text.

The parent-analogue inversion

Tuftsin has roughly 690 indexed records against Selank's 135. For most designed analogues the derivative eventually outgrows the parent, because the parent was abandoned as impractical. Here the reverse holds, reflecting decades of immunological interest in tuftsin that predates and runs parallel to Selank rather than feeding into it. Anyone assessing Selank should know that most of the tuftsin literature is not about Selank at all.

Research material referenced

Selank 10mg — third-party HPLC tested

View — £24.99

What can and cannot be assessed

The mechanistic claims can be evaluated directly — the enkephalinase papers describe what was measured and in what system. The clinical claims are harder to assess independently, not because the work does not exist but because language and access barriers sit between a reader and the methods. Neither dismissing that work nor accepting it uncritically is defensible.

Scale, in context

135 records is a small literature. BPC-157 and TB-500 have accumulated substantially more; a widely used approved medicine has thousands. Selank has been studied consistently but by a relatively narrow set of groups, and that concentration is itself relevant when weighing how independently the findings have been reproduced.

How to search it

PubMed indexes the field under 'Selank', and the development code TP-7 surfaces some older records the name misses. Filtering to English-language records isolates the internationally published mechanistic work; removing that filter shows how much of the clinical record sits outside it. Comparing the two counts is itself informative about the shape of the evidence.

Extended research context

The Selank (Tuftsin Analogue) deep dive

Deep dive: preserving a signal rather than supplying one

Selank's most specifically characterised activity is not receptor binding. Work published in the Bulletin of Experimental Biology and Medicine in 2001 and 2002 reported that it inhibits enkephalin-degrading enzymes, measured directly on plasma enkephalinase activity, thereby extending the half-life of endogenous enkephalins rather than acting at opioid receptors itself. That distinction is routinely muddled and it matters: an agonist activates the receptor wherever the drug reaches, at whatever concentration is given, while a degradation inhibitor only lets the ligand the body is already releasing persist longer. The effect is bounded by endogenous release and occurs only where that release happens. The same logic underlies DPP-4 inhibitors in the incretin field, which prolong native GLP-1 rather than supplying an analogue - and instructively, that class produces much smaller effects than the receptor agonists do.

Deep dive: what the sequence does and does not contain

TKPRPGP is unusual among research peptides for what is absent from it. There is no cysteine, so no disulfide bonds form or scramble and no reducing agent is needed. There is no methionine, so the thioether oxidation that adds 16 Da and dominates handling guidance for MOTS-c and Semax does not apply. There is no asparagine or glutamine either, ruling out deamidation. What remains is straightforward hydrolysis, and three prolines in seven residues resist even enzymatic cleavage well, because proline locks the backbone rotation peptidases require. One practical cost of that composition: no aromatic residues means almost no absorbance at 280 nm, so the standard spectrophotometric quantification method does not work on it.

Deep dive: reading a two-literature evidence base

PubMed indexes roughly 135 Selank records against about 690 for its parent peptide tuftsin - an inversion worth noticing, since most designed analogues eventually outgrow the parent they replaced. Most of the tuftsin literature is immunological and predates Selank entirely, so it is not evidence about Selank. Within Selank's own record the split is the same one Semax shows: mechanistic work in internationally indexed journals, assessable directly; clinical work concentrated in Russian-language publications, indexed by translated title and often without accessible English full text. That is evidence which is hard to verify independently, which is not the same as evidence that is absent, and not the same as evidence that is established.

Research applications

▸Enkephalin and enkephalinase pathway research
▸GABAergic receptor expression studies in rodent models
▸BDNF expression research, including intranasal administration routes
▸Comparative work on proline-stabilised peptide design
▸Tuftsin and immunopeptide structure-activity research

Handling checklist

✓Store lyophilised material cold, dry and protected from light
✓No reducing agent needed — the sequence contains no cysteine
✓No methionine oxidation to expect; a +16 Da satellite warrants explanation
✓Do not rely on 280 nm absorbance — there are no aromatic residues
✓Introduce diluent gently against the vial wall; swirl rather than shake
✓Aliquot to avoid repeated freeze-thaw cycles

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Describing Selank as an opioid or opioid agonist

Fix: Reported work describes inhibition of enkephalin-degrading enzymes, not receptor binding. It preserves endogenous enkephalins rather than supplying an agonist.

✗ Treating the benzodiazepine contrast as a safety claim

Fix: The mechanistic difference is real — expression-level rather than direct allosteric modulation — but it supports no comparative claim about safety or dependence.

✗ Citing tuftsin literature as evidence about Selank

Fix: Tuftsin has roughly five times more papers, most of them immunological and predating Selank. They are different compounds.

✗ Reading a BDNF expression change as a demonstrated outcome

Fix: The work measured expression in rat hippocampus. Expression is upstream of function and upstream again of any clinical claim.

✗ Treating Russian registration as equivalent to MHRA approval

Fix: Authorisations are jurisdictional and do not transfer. Selank has never been assessed by the MHRA, EMA or FDA.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

Are there Western clinical trials of Selank?: No substantial Western clinical programme exists, and no Western regulator has assessed it.
Why does tuftsin have more papers than Selank?: Tuftsin has been studied immunologically for decades independently of Selank. Most of that literature is not about Selank.
Which paper is the best starting point?: The 2001 Bulletin of Experimental Biology and Medicine paper on enkephalin-degrading enzymes, PMID 11550013, describes the most specific reported mechanism.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More Selank (Tuftsin Analogue) articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum